Skip to main content
May 24, 2022
Newly Diagnosed
Treatment & Care
Survivorship
Join the Community
Newsletter
Newly Diagnosed
Treatment & Care
Survivorship
Join the Community
Newsletter
Lyt-200
Pancreatic Cancer Treatment
FDA Grants Orphan Drug Designation to LYT-200 for Pancreatic Cancer and being evaluated in Cholangiocarcinoma
By Dr. C.H. Weaver M.D.
Nov 27, 2021
CLOSE
CLOSE
CLOSE
CLOSE